Madrigal Pharmaceuticals, Inc. MDGL Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s accrued expenses?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported accrued expenses of $34.33M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s accrued expenses changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s accrued expenses increased by 87.9% year-over-year, from $18.27M to $34.33M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s accrued expenses has grown at a 8.9% compound annual growth rate (CAGR), from $45.22M to $69.21M.
- What does accrued expenses mean?
- Expenses that have been incurred but not yet paid or billed.
- How do you interpret accrued expenses?
- Rising accruals often reflect increased operational activity or clinical trial progress, while declining accruals may suggest a slowdown in R&D activity.
- How does accrued expenses compare across companies?
- Commonly tracked across clinical-stage peers to gauge the pace of trial execution.